Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae12 hours ago
Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI) for its Covid-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.
Besides Covaxin, BharatBiotechhas been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose intranasal vaccine for Covid-19
"BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021," an email reply from the city-based vaccine maker told PTI.
Phase I human clinical trials will be conducted in India, Bharat Biotech added. The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit, the company sources said adding Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe.
Krishna Ella, Chairman of Bharat Biotech had earlier said the company is focusing on the intranasal vaccine as the existing vaccines require two dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add up to pollution.
An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive, he had said.
"One drop of vaccine in each of the nostrils is sufficient," he had said. According to him, keeping several issues in mind Bharat Biotech tied up with Washington University School of Medicine for the single dose intranasal vaccine for COVID-19 . He had said Bharat Biotech envisions that it would scale this vaccine to one billion doses, translating into equal number of individuals being vaccinated receiving a single-dose regimen.
BharatBiotech, upon obtaining required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP (good manufacturing practice) facility located in Genome Valley, here, the company had earlier said.
The intranasal vaccine candidate has shown unprecedented levels of protection in mice studies and the technology and data having been already published in the
prestigious scientific journal 'Cell' and in an editorial in 'Nature', the company had said. Bharat Biotech has successfully completed enrollment of 25,800 volunteers for the Phase-3 trials of its Covid-19 vaccine Covaxin.
Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae12 hours ago
10 lucky fans will have the once-in-a-lifetime chance to meet the eight-division world champion
uae attractions12 hours ago
ASAS 2024 brought together over 1,000 young talents from 50 nationalities under the theme 'Art and Innovation'
kt network13 hours ago
While President-elect Trump's administration originally filed the search case against Google during his first term, he indicated he might not break up the company
tech13 hours ago
The gathering explored the cutting edge of cinema, new media, PR and marketing, IT technologies, eSports, and game development
kt network13 hours ago
Passengers were currently being prevented from entering the building
world13 hours ago
Users will be able to select transcript language, too; here's how the new smart tool works
tech13 hours ago
With the new tariff, Yango Ride users can expect comfortable, modern limo vehicles starting from a minimum fare of Dh15.6
kt network14 hours ago